Patents by Inventor Colin Peter Sambrook Smith

Colin Peter Sambrook Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENZYME INHIBITORS
    Publication number: 20220289727
    Abstract: The present invention provides compounds of formula (I) or (Ia) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, n, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 15, 2022
    Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Alessandro MAZZACANI, David Edward CLARK, Paul Stuart HINCHLIFFE, Thomas Matthew BAKER, Colin Peter SAMBROOK SMITH, Alun John SMITH, Joseph William WRIGGLESWORTH, Xuezheng YANG
  • Pharmaceutically Active Compounds
    Publication number: 20210070708
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: July 14, 2020
    Publication date: March 11, 2021
    Applicant: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically active compounds
    Patent number: 10766861
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 8, 2020
    Assignee: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically Active Compounds
    Publication number: 20200010421
    Abstract: The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: May 15, 2019
    Publication date: January 9, 2020
    Applicant: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • Pharmaceutically active compounds
    Patent number: 10336702
    Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 2, 2019
    Assignee: BerGenBio ASA
    Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
  • PHARMACEUTICALLY ACTIVE COMPOUNDS
    Publication number: 20180029985
    Abstract: The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
    Type: Application
    Filed: December 23, 2015
    Publication date: February 1, 2018
    Applicant: BERGENBIO AS
    Inventors: Jason John SHIERS, John Paul WATTS, Stuart Thomas ONIONS, Mohammed Abdul QUDDUS, Joseph William WRIGGLESWORTH, Colin Peter SAMBROOK-SMITH, Alan NAYLOR, Derek LONDESBROUGH
  • Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
    Patent number: 8278442
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 2, 2012
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Tom Banksia Dupree, Peter Timothy Fry, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John Stewart
  • GPCR Agonists
    Publication number: 20120172358
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 5, 2012
    Applicant: Prosidion Limited
    Inventors: Stuart Edward Bradley, Matthew Colin Thor Fyfe, Lisa Sarah Bertram, William Gattrell, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Chrystelle Marie Rasamison, Philip John Rushworth, Colin Peter Sambrook-Smith, David French Stonehouse, Simon Andrew Swain, Geoffrey Martyn Williams
  • Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
    Patent number: 8158622
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 17, 2012
    Assignee: Prosidion Limited
    Inventors: Stuart Edward Bradley, Thomas Martin Krulle, Peter John Murray, Martin James Procter, Robert John Rowley, Colin Peter Sambrook Smith, Gerard Hugh Thomas, Karen Lesley Schofield
  • Compounds for the Treatment of Metabolic Disorders
    Publication number: 20120077793
    Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 29, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Peter Timothy Fry, Matthew Colin Thor Fyfe, William Gattrell, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain
  • Bicyclic aryl and heteroaryl receptor modulators
    Patent number: 8063247
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: November 22, 2011
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
  • PIPERIDINYL GPCR AGONISTS
    Publication number: 20110269734
    Abstract: Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: November 3, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, John Keily, Thomas Martin Krulle, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Simon Andrew Swain
  • Heterocyclic GPCR Agonists
    Publication number: 20110212939
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: September 1, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Philip Graham Clarke, Graham John Dawson, Peter Timothy Fry, Matthew Colin Thor Fyfe, William Gattrell, Revathy Perpetua Jeevaratnam, John Keily, Thomas Martin Krulle, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Simon Andrew Swain
  • Integrin antagonists useful as anticancer agents
    Patent number: 8003806
    Abstract: The invention relates to compounds of the Formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X2, X4, X5 and X1 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula 1.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: August 23, 2011
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Jason Bloxham, Gary V. Borzillo, Eric William Collington, Shazia Sadiq, Colin Peter Sambrook Smith, Chris L. Waller, Graham M. Wynne
  • Azetidinyl G-Protein Coupled Receptor Agonists
    Publication number: 20110059942
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.
    Type: Application
    Filed: October 20, 2008
    Publication date: March 10, 2011
    Inventors: Matthew ColinThor Fyfe, William Gattrell, Colin Peter Sambrook-Smith, Simon Andrew Swain
  • AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS
    Publication number: 20100286110
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 11, 2010
    Inventors: Matthew Colin Thor Fyfe, William Gattrell, Colin Peter Sambrook-Smith
  • BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS
    Publication number: 20100267780
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
    Type: Application
    Filed: September 8, 2008
    Publication date: October 21, 2010
    Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
  • N-substituted imidazopyridine c-Kit inhibitors
    Patent number: 7767673
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-Oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 3, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Andrew P. Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
    Publication number: 20100173886
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
    Type: Application
    Filed: May 22, 2008
    Publication date: July 8, 2010
    Inventors: Jason Bloxham, Stuart Edward Bradley, Tom Banksia Dupree, Peter Timothy Fry, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John Stewart
  • AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES
    Publication number: 20100093733
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.
    Type: Application
    Filed: February 15, 2008
    Publication date: April 15, 2010
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Graham Dawson, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Philippe Wong-Kai-In